Co-Diagnostics, Inc. (CODX) is facing a class action lawsuit (Co-Diagnostics Class Action Lawsuit) alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) demand for the Company’s Logix Smart™ COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants’ positive statements about the demand for its Logix Smart™ COVID-19 test lacked a reasonable basis.
If you incurred a loss on CODX stocks purchased between May 12, 2022 and August 11, 2022, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Southern District of New York, and our firm is reaching out to investors to discuss their legal rights.
If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.
You only have until October 17, 2022 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.
Co-Diagnostics, Inc. Class Action Lawsuit
Co-Diagnostics, Inc. Lawsuit
CODX Class Action Lawsuit
CODX Lawsuit
Co-Diagnostics, Inc. (CODX) Class Action Lawsuit
Co-Diagnostics Class Action Lawsuit,
Co-Diagnostics Class Action,
Co-Diagnostics Lawsuit,
CODX Class Action Lawsuit,
CODX Class Action,
CODX Lawsuit,
CODX stock